

TIROSINT- levothyroxine sodium capsule

IBSA Pharma Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TIROSINT® safely and effectively. See full prescribing information for TIROSINT.

TIROSINT® (levothyroxine sodium) capsules, for oral use

Initial U.S. Approval: 2000

WARNING: NOT FOR TREATMENT OF OBESITY or FOR WEIGHT LOSS

See full prescribing information for complete boxed warning

- **Thyroid hormones, including TIROSINT, should not be used for the treatment of obesity or for weight loss.**
- **Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity (6, 10).**

INDICATIONS AND USAGE

TIROSINT is L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with:

- Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism (1)
- Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer (1)

Limitations of Use:

- Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients (1)
- Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis (1)

DOSAGE AND ADMINISTRATION

- Administer once daily, on an empty stomach, one-half to one hour before breakfast (2.1)
- Administer at least 4 hours before or after drugs that are known to interfere with absorption (2.1)
- Evaluate the need for dose adjustments when regularly administering within an hour of certain foods that may affect TIROSINT absorption (2.1)
- Swallow TIROSINT capsules whole, do not cut, crush, or chew (2.1)
- Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food, and the specific nature of the condition being treated. Peak therapeutic effect may not be attained for 4-6 weeks (2.2)
- See full prescribing information for dosing in specific patient populations (2.3)
- Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status (2.4)

DOSAGE FORMS AND STRENGTHS

Capsules: 13, 25, 37.5, 44, 50, 62.5, 75, 88, 100, 112, 125, 137, 150, 175, 200 mcg (3)

CONTRAINDICATIONS

- Uncorrected adrenal insufficiency (4)

WARNINGS AND PRECAUTIONS

- *Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease:* Initiate TIROSINT at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (2.3, 5.1, 8.5)
- *Myxedema coma:* Do not use oral thyroid hormone drug products to treat myxedema coma. (5.2)

- *Acute adrenal crisis in patients with concomitant adrenal insufficiency:* Treat with replacement glucocorticoids prior to initiation of TIROSINT treatment. (5.3)
- *Prevention of hyperthyroidism or incomplete treatment of hypothyroidism:* Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism. (5.4)
- *Worsening of diabetic control:* Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy. (5.5)
- *Decreased bone mineral density associated with thyroid hormone over-replacement:* Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose. (5.6)

-----ADVERSE REACTIONS-----

Adverse reactions associated with TIROSINT are primarily those of hyperthyroidism due to therapeutic overdosage including: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash (6)

To report SUSPECTED ADVERSE REACTIONS, contact IBSA Pharma Inc. at 1-800-587-3513, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

-----DRUG INTERACTIONS-----

See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to TIROSINT (7)

-----USE IN SPECIFIC POPULATIONS-----

Pregnancy may require the use of higher doses of TIROSINT (2.3, 8.1)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 10/2022

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: NOT FOR TREATMENT OF OBESITY or FOR WEIGHT LOSS

1 INDICATION AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 General Administration Information
- 2.2 General Principles of Dosing
- 2.3 Dosing In Specific Patient Populations
- 2.4 Monitoring TSH and/or Thyroxine (T4) Levels

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease
- 5.2 Myxedema Coma
- 5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency
- 5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism
- 5.5 Worsening of Diabetic Control
- 5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

- 7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

- 7.2 Antidiabetic Therapy
- 7.3 Oral Anticoagulants
- 7.4 Digitalis Glycosides
- 7.5 Antidepressant Therapy
- 7.6 Ketamine
- 7.7 Sympathomimetics
- 7.8 Tyrosine-Kinase Inhibitors
- 7.9 Drug-Food Interactions
- 7.10 Drug-Laboratory Test Interactions

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: NOT FOR TREATMENT OF OBESITY or FOR WEIGHT LOSS

- Thyroid hormones, including TIROSINT, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.
- In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
- Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [*see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)*].

1 INDICATION AND USAGE

Hypothyroidism

TIROSINT is indicated as a replacement therapy in adults and pediatric patients 6 years and older with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression

TIROSINT is indicated as an adjunct to surgery and radioiodine therapy in the management of adults and pediatric patients 6 years and older with thyrotropin-dependent well-differentiated thyroid cancer.

Limitations of Use:

- TIROSINT is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with TIROSINT may induce hyperthyroidism [see *Warnings and Precautions* (5.4)].
- TIROSINT is not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis.

2 DOSAGE AND ADMINISTRATION

2.1 General Administration Information

Administer TIROSINT as a single daily oral dose, on an empty stomach, one-half to one hour before breakfast.

Administer TIROSINT at least 4 hours before or after drugs known to interfere with TIROSINT absorption [see *Drug Interactions* (7.1)]

Evaluate the need for dose adjustments when regularly administering within an hour of certain foods that may affect TIROSINT absorption [see *Drug Interactions* (7.9) and *Clinical Pharmacology* (12.3)].

Swallow TIROSINT capsules whole, do not cut, crush, or chew.

2.2 General Principles of Dosing

The dose of TIROSINT for hypothyroidism or pituitary TSH suppression depends on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food, and the specific nature of the condition being treated [see *Dosage and Administration* (2.3), *Warnings and Precautions* (5), and *Drug Interactions* (7)] . Dosing must be individualized to account for these factors and dose adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see *Dosage and Administration* (2.4)].

The peak therapeutic effect of a given dose of TIROSINT may not be attained for 4 to 6 weeks.

2.3 Dosing In Specific Patient Populations

Primary Hypothyroidism in Adults and in Adolescents in Whom Growth and Puberty are Complete

Start TIROSINT at the full replacement dose in otherwise healthy, non-elderly individuals who have been hypothyroid for only a short time (such as a few months). The average full replacement dose of TIROSINT is approximately 1.6 mcg per kg per day (for example: 100-125 mcg per day for a 70 kg adult).

Adjust the dose by 12.5 to 25 mcg increments every 4 to 6 weeks until the patient is clinically euthyroid and the serum TSH returns to normal. Doses greater than 200 mcg per day are seldom required. An inadequate response to daily doses greater than 300 mcg per day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.

For elderly patients or patients with underlying cardiovascular disease, start with a dose of 12.5 to 25 mcg per day. Increase the dose every 6 to 8 weeks, as needed, until the patient is clinically euthyroid and the serum TSH returns to normal. The full replacement dose of TIROSINT may be less than 1 mcg per kg per day in elderly patients.

In patients with severe longstanding hypothyroidism, start with a dose of 12.5 to 25 mcg per day. Adjust the dose in 12.5 to 25 mcg increments every 2 to 4 weeks until the patient is clinically euthyroid and the serum TSH level is normalized.

Secondary or Tertiary Hypothyroidism

Start TIROSINT at the full replacement dose in otherwise healthy, non-elderly individuals. Start with a lower dose in elderly patients with underlying cardiovascular disease or patients with severe longstanding hypothyroidism as described above. Serum TSH is not a reliable measure of TIROSINT dose adequacy in patients with secondary or tertiary hypothyroidism, and should not be used to monitor therapy. Use the serum free-T4 level to monitor adequacy of therapy in this patient population. Titrate TIROSINT dosing per above instructions until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range.

Pediatric Dosage - Congenital or Acquired Hypothyroidism

Only administer TIROSINT to pediatric patients 6 years and older who are able to swallow an intact capsule .

The recommended daily dose of TIROSINT in pediatric patients with hypothyroidism is based on body weight and changes with age as described in Table 1. Start TIROSINT at the full daily dose in most pediatric patients. Start at a lower dose in children at risk for hyperactivity (see below). Monitor for clinical and laboratory response [see *Dosage and Administration* (2.4)] .

Table 1: TIROSINT Dosing Guidelines for Pediatric Hypothyroidism

Age	Daily Dose Per Kg Body Weight *
6-12 years	4-5 mcg/kg/day
Greater than 12 years but growth and puberty incomplete	2-3 mcg/kg/day
Growth and puberty complete	1.6 mcg/kg/day

* The dose should be adjusted based on clinical response and laboratory parameters [see *Dosage and Administration* (2.4) and *Use in Specific Populations* (8.4)] .

Children at risk for hyperactivity: To minimize the risk of hyperactivity in children, start at one-fourth the recommended full replacement dose, and increase on a weekly basis by one-fourth the full-recommended replacement dose until the full recommended replacement dose is reached.

Pregnancy

Preexisting Hypothyroidism: TIROSINT dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at a minimum, during each trimester of pregnancy. In patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. For patients with serum TSH above the normal trimester specific range, increase the dose of TIROSINT by 12.5 to 25 mcg per day and measure TSH every four weeks until a stable TIROSINT dose is reached and serum TSH is within the normal trimester specific range. Reduce TIROSINT dosage to pre-pregnancy levels immediately after delivery and measure serum TSH levels 4 to 8 weeks postpartum to ensure the TIROSINT dose is appropriate.

New Onset Hypothyroidism: Normalize thyroid function as rapidly as possible. In patients with moderate to severe signs and symptoms of hypothyroidism, start TIROSINT at the full replacement dose (1.6 mcg per kg body weight per day). In patients with mild hypothyroidism (TSH < 10 mIU per Liter), start TIROSINT at 1.0 mcg per kg body weight per day. Evaluate serum TSH every 4 weeks and adjust TIROSINT dosage until serum TSH is within the normal trimester specific range [see *Use in Specific Populations (8.1)*].

TSH Suppression in Well-Differentiated Thyroid Cancer

Generally, TSH is suppressed to below 0.1 mIU per Liter, and this usually requires a TIROSINT dose of greater than 2 mcg per kg per day. However, in patients with high-risk tumors, the target level for TSH suppression may be lower.

2.4 Monitoring TSH and/or Thyroxine (T4) Levels

Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of TIROSINT may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.

Adults

In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dose. In patients on a stable and appropriate replacement dose, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient's clinical status.

Pediatrics

In patients with congenital hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in children as follows: at 2 and 4 weeks after the initiation of treatment 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dose stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of mental and physical growth and development, and bone maturation at regular intervals.

While the general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to *in utero* hypothyroidism causing a resetting of the pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of TIROSINT therapy and/or of the serum TSH to decrease below 20 mIU per Liter within 4 weeks may indicate the child is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of TIROSINT [see *Warnings and Precautions* (5.4) and *Use in Specific Populations* (8.4)] .

Secondary (Pituitary) and Tertiary (Hypothalamic) Hypothyroidism

Monitor serum free-T4 levels maintain in the upper half of the normal range in these patients.

3 DOSAGE FORMS AND STRENGTHS

TIROSINT capsules are amber-colored, round/biconvex capsules, imprinted with a dosage strength specific letter on one side and containing a viscous amber-colored liquid and are available as follows:

Strength (mcg)	Imprint Code
13	<u>A</u>
25	<u>E</u>
37.5	<u>O</u>
44	<u>R</u>
50	<u>G</u>
62.5	<u>L</u>
75	<u>H</u>
88	<u>J</u>
100	<u>K</u>
112	<u>M</u>
125	<u>N</u>
137	<u>P</u>
150	<u>S</u>
175	<u>U</u>
200	<u>Y</u>

4 CONTRAINDICATIONS

TIROSINT is contraindicated in patients with uncorrected adrenal insufficiency [see *Warnings and Precautions* (5.3)].

5 WARNINGS AND PRECAUTIONS

5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease

Overtreatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate TIROSINT therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see *Dosage and Administration (2.3) and Use in Specific Populations (8.5)*].

Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive TIROSINT therapy. Monitor patients receiving concomitant TIROSINT and sympathomimetic agents for signs and symptoms of coronary insufficiency. If cardiac symptoms develop or worsen, reduce the TIROSINT dose or withhold it for one week and restart at a lower dose.

5.2 Myxedema Coma

Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.

5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency

Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy precipitate an acute adrenal crisis in patient with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with TIROSINT [see *Contraindications (4)*].

5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism

TIROSINT has a narrow therapeutic index. Over- or under-treatment with TIROSINT may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and on glucose and lipid metabolism. Titrate the dose of TIROSINT carefully and monitor response to titration to avoid these effects [see *Dosage and Administration (2.4)*]. Monitor for the presence of drug or food interactions when using TIROSINT and adjust the dose as necessary [see *Drug Interactions (7) and Clinical Pharmacology (12.3)*].

5.5 Worsening of Diabetic Control

Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy [see *Drug Interactions (7.2)*].

5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

Increased bone resorption and decreased bone mineral density may occur as a result of

levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of TIROSINT that achieves the desired clinical and biochemical response to mitigate against this risk.

6 ADVERSE REACTIONS

Adverse reactions associated with TIROSINT therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see *Warnings and Precautions (5) and Overdosage (10)*]. They include the following:

- *General*: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
- *Central nervous system*: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
- *Musculoskeletal*: tremors, muscle weakness, muscle spasm
- *Cardiovascular*: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
- *Respiratory*: dyspnea
- *Gastrointestinal (GI)*: diarrhea, vomiting, abdominal cramps, elevations in liver function tests
- *Dermatologic*: hair loss, flushing, rash
- *Endocrine*: decreased bone mineral density
- *Reproductive*: menstrual irregularities, impaired fertility

Seizures have been reported rarely with the institution of levothyroxine therapy.

Adverse Reactions in Children

Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height.

Hypersensitivity Reactions

Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various GI symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.

7 DRUG INTERACTIONS

7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

Many drugs can exert effects thyroid hormone pharmacokinetics (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to TIROSINT (see Tables 2 to 5 below).

**Table 2: Drugs That May Decrease T4 Absorption
(Hypothyroidism)**

Potential impact: Concurrent use may reduce the efficacy of TIROSINT by binding and delaying or preventing absorption, potentially resulting in hypothyroidism	
Drug or Drug Class	Effect
Calcium Carbonate Ferrous Sulfate	Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. Administer TIROSINT at least 4 hours apart from these agents.
Orlistat	Monitor patients treated concomitantly with orlistat and TIROSINT for changes in thyroid function.
Bile Acid Sequestrants -Colesevelam -Cholestyramine -Colestipol Ion Exchange Resins -Kayexalate -Sevelamer	Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer TIROSINT at least 4 hours prior to these drugs or monitor thyrotropin (TSH) levels.
Other drugs: Proton Pump Inhibitors Sucralfate Antacids - Aluminum & Magnesium Hydroxides - Simethicone	Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately

Table 3: Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)

Drug or Drug Class	Effect
Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen	These drugs may increase serum thyroxine-binding globulin (TBG) concentration.
Androgens / Anabolic Steroids Asparaginase Glucocorticoids	These drugs may decrease serum TBG concentration.

Slow-Release Nicotinic Acid	
Potential impact (below) : Administration of these agents with TIROSINT results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.	
Salicylates (> 2 g/day)	Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.
Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs - Fenamates	These drugs may cause protein-binding site displacement . Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increased free-T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free-T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.

Table 4: Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)

Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased TIROSINT requirements.	
Drug or Drug Class	Effect
	Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT)

Phenobarbital Rifampin	glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.
---------------------------	---

Table 5: Drugs That May Decrease Conversion of T4 to T3

Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.	
Drug or Drug Class	Effect
Beta-adrenergic antagonists (e.g., Propranolol > 160 mg/day)	In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.
Glucocorticoids (e.g., Dexamethasone \geq 4 mg/day)	Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see Table 3 above).
Other: Amiodarone	Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decrease or normal free-T3) in clinically euthyroid patients.

7.2 Antidiabetic Therapy

Addition of TIROSINT therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Careful monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [*see Warnings and Precautions (5.5)*] .

7.3 Oral Anticoagulants

TIROSINT increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the TIROSINT dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.

7.4 Digitalis Glycosides

TIROSINT may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.

7.5 Antidepressant Therapy

Concurrent use of tricyclic (e.g., Amitriptyline) or tetracyclic (e.g., Maprotiline) antidepressants and TIROSINT may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. TIROSINT may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on TIROSINT may result in increased TIROSINT requirements.

7.6 Ketamine

Concurrent use of ketamine and TIROSINT may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.

7.7 Sympathomimetics

Concurrent use of sympathomimetics and TIROSINT may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.

7.8 Tyrosine-Kinase Inhibitors

Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.

7.9 Drug-Food Interactions

Consumption of certain foods may affect TIROSINT absorption thereby necessitating adjustments in dosing [*see Dosage and Administration (2.1)*] . Soybean flour (infant formula), cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of TIROSINT from the GI tract. Grapefruit juice may delay the absorption of

levothyroxine and reduce its bioavailability.

7.10 Drug-Laboratory Test Interactions

Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, and androgens and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages [see *Data*]. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since thyroid-stimulating hormone (TSH) levels may increase during pregnancy, TSH should be monitored and TIROSINT dosage adjusted during pregnancy [see *Clinical Considerations*]. There are no animal studies conducted with levothyroxine during pregnancy. TIROSINT should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryo/Fetal Risk

Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.

Dose Adjustments During Pregnancy and the Postpartum Period

Pregnancy may increase TIROSINT requirements. Serum TSH level should be monitored and the TIROSINT dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the TIROSINT dosage should return to the pre-pregnancy dose immediately after delivery [see *Dosage and Administration (2.3)*].

Data

Human Data

Levothyroxine is approved for use as a replacement therapy for hypothyroidism. There

is a long experience of levothyroxine use in pregnant women, including data from post-marketing studies that have not reported increased rates of fetal malformations, miscarriages or other adverse maternal or fetal outcomes associated with levothyroxine use in pregnant women.

8.2 Lactation

Risk Summary

Limited published studies report that levothyroxine is present in human milk. However, there is insufficient information to determine the effects of levothyroxine on the breastfed infant and no available information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TIROSINT and any potential adverse effects on the breastfed infant from TIROSINT or from the underlying maternal condition.

8.4 Pediatric Use

TIROSINT is indicated for use in pediatric patients 6 years and older. The initial dose of TIROSINT varies with age and body weight. Dosing adjustments are based on an assessment of the individual patient's clinical and laboratory parameters [*see Dosage and Administration (2.3, 2.4)*]

In children in whom a diagnosis of permanent hypothyroidism has not been established, discontinue TIROSINT administration for a trial period. Obtain serum T4 and TSH levels at the end of the trial period, and use laboratory test results and clinical assessments to guide diagnosis and treatment, if warranted.

Congenital Hypothyroidism [*see Dosage and Administration (2.3, 2.4)*]

Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, initiate levothyroxine therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients.

Closely monitor children during the first two weeks of TIROSINT therapy for cardiac overload and arrhythmias.

Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment may adversely affect the tempo of brain maturation and accelerate the bone age with resultant premature closure of the epiphyses and compromised adult stature.

Acquired Hypothyroidism in Pediatric Patients

Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.

Treated children may manifest a period of catch-up growth, which may be adequate in

some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.

8.5 Geriatric Use

Because of the increased prevalence of cardiovascular disease among the elderly, initiate TIROSINT therapy at less than the full replacement dose [see *Warnings and Precautions (5.1)* and *Dosage and Administration (2.3)*]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly .

10 OVERDOSAGE


The signs and symptoms of overdose are those of hyperthyroidism [see *Warnings and Precautions (5)* and *Adverse Reactions (6)*]. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year-old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

Reduce the TIROSINT dose or discontinue temporarily if signs or symptoms of overdose occur. Initiate appropriate supportive treatment as dictated by the patient's medical status.

For current information on the management of poisoning or overdose, contact the National Poison Control Center at 1-800-222-1222 or www.poisson.org.

11 DESCRIPTION

TIROSINT (levothyroxine sodium) capsules for oral use contain synthetic L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T₄) sodium]. Synthetic T₄ is chemically identical to that produced in the human thyroid gland. Levothyroxine (T₄) sodium has an empirical formula of C₁₅H₁₀I₄NNaO₄ • x H₂O (where x = 5), molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:



TIROSINT (levothyroxine sodium) capsules are amber-colored, round/biconvex capsules containing a viscous amber-colored liquid.

The inactive ingredients in TIROSINT are gelatin, glycerin and water.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.

The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

12.2 Pharmacodynamics

Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.

12.3 Pharmacokinetics

Absorption

Absorption of orally administered T₄ from the gastrointestinal (GI) tract ranges from 40% to 80%. The majority of the levothyroxine dose is absorbed from the jejunum and upper ileum. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases the bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption. *[see Drug Interactions (7)]*

Distribution

Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and thyroxine-binding albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins *[see Drug Interactions (7)]*. Thyroid hormones do not readily cross the placental barrier *[see Use in Specific Populations (8.1)]*.

Elimination

Metabolism

T4 is slowly eliminated (see Table 6) . The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.

Excretion

Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.

Table 6: Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients

Hormone	Ratio in Thyroglobulin	Biologic Potency	Half-Life (Days)	Protein Binding (%) *
Levothyroxine (T4)	10 - 20	1	6 - 7 †	99.96
Liothyronine (T3)	1	4	≤ 2	99.5

* Includes TBG, TBPA and TBA.

† 3 - 4 days in hyperthyroidism, 9 - 10 days in hypothyroidism.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of levothyroxine sodium.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

TIROSINT (levothyroxine sodium) capsules are amber-colored, round/biconvex capsules, imprinted with a dosage strength specific letter on one side and containing a viscous amber-colored liquid. They are supplied as follows:

Table 7: TIROSINT Packaging Description - Boxes of 30 capsules, consisting of 3 blisters with 10 capsules each

Strength (mcg)	Color *	Imprint Code	NDC
13	Green	A	71858-0005-4
25	Orange	E	71858-0010-4
37.5	Dark Blue	O	71858-0012-4
44	Red	R	71858-0013-4
50	White	G	71858-0015-4
62.5	Grey	L	71858-0017-4
75	Purple	H	71858-0020-4
88	Olive	J	71858-0025-4
100	Yellow	K	71858-0030-4

112	Rose	M	71858-0035-4
125	Brown	N	71858-0040-4
137	Turquoise	P	71858-0045-4
150	Blue	S	71858-0050-4
175	Lilac	U	71858-0055-4
200	Pink	Y	71858-0060-4

* Shown on box and blister packing, not on individual capsules.

The dosage strength on each box is clearly identified in several locations, and is associated with a distinct color. The color of the circles on the blister is the same color as on the box. Each blister pack contains 10 capsules placed in individual cavities labeled with the dosage strength and the product name (TIROSINT).

16.2 Storage and Handling

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°-30°C (59-86°F) [see USP Controlled Room Temperature]. TIROSINT capsules should be protected from heat, light and moisture.

Do not separate the individual cavities containing the drug from the intact blister as important information may be lost (i.e., manufacturer/distributor names, distributor contact phone number, lot number, and expiration date), and do not remove the individual capsules from blister packaging until ready to use.

17 PATIENT COUNSELING INFORMATION

Advise the patient and/or the caregiver to read the FDA-approved patient labeling (Patient Information Sheet).

Dosing and Administration

- Instruct patients to take TIROSINT only as directed by their healthcare provider.
- Instruct patients to take TIROSINT one-half to one hour before breakfast.
- Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take TIROSINT within 4 hours of these agents.
- Instruct patients that TIROSINT capsules should be swallowed whole and never be cut, crushed, or chewed.
- To assist with identifying the name and strength of each TIROSINT capsule, instruct patients not to remove capsules from the blisters in advance, particularly if they are taking multiple strengths.
- Instruct patients to notify their healthcare provider should they become pregnant or are thinking of becoming pregnant while taking TIROSINT.

Important Information

- Inform patients that it may take several weeks before they notice an improvement in symptoms.
- Inform patients that the levothyroxine in TIROSINT is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.
- Inform patients that TIROSINT should not be used as a primary or adjunctive therapy

in a weight control program.

- Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations [see *Drug Interactions (7)*].
- Instruct patients to notify their healthcare provider of any other medical conditions, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while taking TIROSINT. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.
- Instruct patients to notify their physician or dentist that they are taking TIROSINT prior to any surgery.

Adverse Reactions

- Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
- Inform patients that partial hair loss may occur rarely during the first few months of TIROSINT therapy, but this is usually temporary.

Manufactured for IBSA Pharma Inc. by:

IBSA Institut Biochimique SA

6912 Pazzallo

Switzerland

Distributed by:

IBSA Pharma Inc.,

Parsippany, NJ 07054

USA

PATIENT INFORMATION

TIROSINT® [tee-row-sent]

(levothyroxine sodium)

capsules, for oral use

What is the most important information I should know about TIROSINT?

- **Do not use TIROSINT to treat weight problems or weight loss.**
- **Do not take more TIROSINT than your doctor prescribes for you to take. Over dosage or taking too much TIROSINT may cause life-threatening side effects or death.**

What is TIROSINT?

TIROSINT is a prescription medicine that contains a hormone called levothyroxine which is normally produced by the thyroid gland. TIROSINT is used to treat adults and children 6 years of age or older:

- to replace or give extra levothyroxine in people whose thyroid does not produce enough of this hormone.
- who need surgery and radioiodine therapy to manage a type of thyroid cancer called thyroid-dependent well-differentiated thyroid cancer.

TIROSINT should not be used to treat people who are recovering from swelling of the thyroid gland (thyroiditis) and whose bodies do not produce enough levothyroxine for a short time.

TIROSINT is unsuitable for children less than 6 years of age or who may be unable to swallow an intact capsule.

Do not take TIROSINT:

- if your adrenal glands are not working well and you have not been treated for this problem.

Before you take TIROSINT, tell your doctor about all of your medical conditions, including if you:

- have or had heart problems.
- have or had thyroid nodules.
- have kidney or pituitary gland problems.
- have any food or drug allergies.
- have a low red blood cell count (anemia).
- have diabetes.
- have weak bones (osteoporosis).
- have or had a history of blood clotting problems.
- have recently received radiation therapy with iodine (such as I-131).
- are pregnant or plan to become pregnant. TIROSINT may harm your unborn baby. Your doctor may need to change your TIROSINT dose while you are pregnant.
- are breastfeeding. TIROSINT can pass into your milk. Talk to your doctor about the best way to feed your baby if you take TIROSINT.

Tell your doctor about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. TIROSINT may affect the way other medicines work, and other medicines may affect how TIROSINT works. You can ask your doctor or pharmacist for a list of medicines that interact with TIROSINT.

How should I take TIROSINT?

- Take TIROSINT exactly as your doctor tells you to take it.
- Your doctor will tell you how much TIROSINT to take each day.
- **Swallow TIROSINT capsules whole.** Do not cut, crush, or chew TIROSINT capsules before swallowing. If you or your child cannot swallow TIROSINT capsules whole, tell your doctor. You may need a different medicine.
- Your doctor may change your dose, if needed.
- Take your dose of TIROSINT 1 time each day, 30 minutes to 1 hour before breakfast,

on an empty stomach.

- Certain medicines can interfere with how TIROSINT is absorbed by your body. Take TIROSINT:
 - **at least 4 hours before or after** you take medicines that contain calcium carbonate or iron (ferrous sulfate).
 - **at least 4 hours before** you take medicines that contain bile acid sequestrants or ion exchange resins.
- **Know the medicines that you take. Ask your doctor or pharmacist for a list of these medicines, if you are not sure.**
- Certain foods including soybean flour, cotton seed meal, walnuts, and dietary fiber can affect your treatment and dose of TIROSINT. Talk to your doctor if you eat or drink these foods.
- **Do not** remove TIROSINT capsules from the original blister package until you are ready to take them.
- Your doctor should do certain blood tests while you are taking TIROSINT and may change your daily dose of TIROSINT as needed. You should not stop taking TIROSINT or change your dose unless your doctor tells you to.
- It may take weeks before you notice your symptoms getting better. Keep using this medicine even if you feel well.
- If you take too much TIROSINT or overdose, call your doctor or poison control center at 1-800-222-1222, or go to the nearest hospital emergency room right away.

What are the possible side effects of TIROSINT?

TIROSINT may cause serious side effects, including:

- **heart problems. You may experience an increased heart rate, chest pain and irregular heartbeat.** Your risk of developing heart problems may be greater if you are elderly, have heart problems, or if you take too much TIROSINT. Your doctor may reduce your dose or stop treatment with TIROSINT for a while if you develop heart problems.
- **worsening diabetic control.** If you are diabetic, it may be harder to control your blood sugar levels causing hyperglycemia while taking TIROSINT. Check your blood sugar levels closely after starting, changing, or stopping treatment with TIROSINT. Your doctor may have to change your diabetes treatment plan.
- **weak or brittle bones.** Your risk of developing weak or brittle bones may be greater if you are post-menopausal or you take too much TIROSINT.

The most common side effects of TIROSINT include:

- | | | |
|-----------------------|----------------------|-------------------------------|
| • irregular heartbeat | • irritability | • vomiting |
| • chest pain | • sleep problems | • diarrhea |
| • shortness of breath | (insomnia) | • sweating a lot |
| • leg cramps | • tremors | • heat intolerance |
| • headache | • muscle weakness | • fever |
| • nervousness | • change in appetite | • changes in menstrual period |
| • hives or skin rash | • weight loss | |

Other side effects may include:

- partial hair loss during the first months of treatment with TIROSINT. This usually lasts a short period of time (temporary).

These are not all the possible side effects of TIROSINT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to IBSA Pharma Inc. at 1-800-587-3513 or www.fda.gov/medwatch.

How should I store TIROSINT?

- Store TIROSINT at room temperature between 68°F to 77°F (20°C to 25°C).
- Store TIROSINT away from heat, light, and moisture.
- Keep TIROSINT in the original blister pack until you are ready to use it.

Keep TIROSINT and all medicines out of the reach of children.

General information about the safe and effective use of TIROSINT

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TIROSINT for a condition for which it was not prescribed. Do not give TIROSINT to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about TIROSINT that is written for health professionals.

What are the ingredients in TIROSINT?

Active ingredient : levothyroxine sodium

Inactive ingredients: gelatin, glycerin, and water

Manufactured by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland;

Marketed and distributed by: IBSA Pharma Inc., Parsippany, NJ 07054 USA

For more information, go to www.tirosint.com or call 1-800-587-3513.

This Patient Information has been approved by the U.S.
Food and Drug Administration

Issued: October 2022

PRINCIPAL DISPLAY PANEL - 13 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0005-4

13 mcg

per capsule

Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules



PRINCIPAL DISPLAY PANEL - 25 mcg Capsule Blister Pack Carton

TIROSINT®

(levothyroxine sodium) capsules

NDC 71858-0010-4

25 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA



PRINCIPAL DISPLAY PANEL - 37.5 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0012-4

37.5 mcg per capsule

Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R x Only

3 blisters x 10 capsules

IBSA





PRINCIPAL DISPLAY PANEL - 44 mcg Capsule Blister Pack Carton

TIROSINT ®

(levothyroxine sodium) capsules

NDC 71858-0013-4

44 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R x Only

3 blisters x 10 capsules

IBSA



PRINCIPAL DISPLAY PANEL - 50 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0015-4

50 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use


Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA





PRINCIPAL DISPLAY PANEL - 62.5 mcg Capsule Blister Pack Carton

TIROSINT ®

(levothyroxine sodium) capsules

NDC 71858-0017-4

62.5 mcg per capsule

Do not remove individual capsules from blister packaging until ready to use


Swallow capsule whole. Do not cut, crush, or chew.

R x Only

3 blisters x 10 capsules

IBSA





PRINCIPAL DISPLAY PANEL - 75 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0020-4

75 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA



PRINCIPAL DISPLAY PANEL - 88 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0025-4

88 mcg per capsule

Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA





PRINCIPAL DISPLAY PANEL - 100 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0030-4

100 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA



PRINCIPAL DISPLAY PANEL - 112 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0035-4

112 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA





PRINCIPAL DISPLAY PANEL - 125 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0040-4

125 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA





PRINCIPAL DISPLAY PANEL - 137 mcg Capsule Blister Pack Carton

TIROSINT®

(levothyroxine sodium) capsules

NDC 71858-0045-4


137 mcg per capsule

Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules



PRINCIPAL DISPLAY PANEL - 150 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0050-4

150 mcg per capsule

Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA





PRINCIPAL DISPLAY PANEL - 175 mcg Capsule Blister Pack Carton

TIROSINT®

(levothyroxine sodium) capsules

NDC 71858-0055-4

175 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA



PRINCIPAL DISPLAY PANEL - 200 mcg Capsule Blister Pack Carton

TIROSINT[®]

(levothyroxine sodium) capsules

NDC 71858-0060-4

200 mcg per capsule


Do not remove individual capsules from blister packaging until ready to use

Swallow capsule whole. Do not cut, crush, or chew.

R_x Only

3 blisters x 10 capsules

IBSA



TIROSINT

levothyroxine sodium capsule

Product Information				
Product Type		HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0013
Route of Administration		ORAL		
Active Ingredient/Active Moiety				
Ingredient Name			Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)			LEVOTHYROXINE SODIUM ANHYDROUS	44 ug
Inactive Ingredients				
Ingredient Name				Strength
GLYCERIN (UNII: PDC6A3C0OX)				
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)				
WATER (UNII: 059QF0KO0R)				
Product Characteristics				
Color	brown	Score	no score	
Shape	OVAL	Size	7mm	
Flavor		Imprint Code	R	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0013-4	3 in 1 CARTON	03/01/2023	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0013-1	1 in 1 CARTON	03/01/2023	

2	10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	03/01/2023	

TIROSINT				
levothyroxine sodium capsule				
Product Information				
Product Type		HUMAN PRESCRIPTION DRUG	Item Code (Source)	
Route of Administration		ORAL	NDC:71858-0012	
Active Ingredient/Active Moiety				
Ingredient Name			Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)			LEVOTHYROXINE SODIUM ANHYDROUS	37.5 ug
Inactive Ingredients				
Ingredient Name				Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)				
GLYCERIN (UNII: PDC6A3C0OX)				
WATER (UNII: 059QF0KO0R)				
Product Characteristics				
Color	brown	Score	no score	
Shape	OVAL	Size	7mm	
Flavor		Imprint Code	O	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0012-4	3 in 1 CARTON	03/01/2023	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0012-1	1 in 1 CARTON	03/01/2023	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	03/01/2023	

TIROSINT

levothyroxine sodium capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0005
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	13 ug

Inactive Ingredients

Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics

Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	A
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0005-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0005-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0010
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	25 ug

Inactive Ingredients

Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics

Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	E
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0010-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0010-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0015
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	50 ug

Inactive Ingredients

Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics

Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	G
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0015-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0015-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0020
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	75 ug

Inactive Ingredients	
Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics			
Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	H
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0020-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0020-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

NDA	NDA021924	12/01/2018	
-----	-----------	------------	--

TIROSINT
levothyroxine sodium capsule

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0025
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	88 ug

Inactive Ingredients	
Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics			
Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	J
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0025-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0025-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0030
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	100 ug

Inactive Ingredients

Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics

Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	K
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0030-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0030-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0035
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	112 ug

Inactive Ingredients

Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics

Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	M
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0035-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0035-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0040
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	125 ug

Inactive Ingredients

Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics

Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	N
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0040-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0040-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0045	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)		LEVOTHYROXINE SODIUM ANHYDROUS	137 ug	
Inactive Ingredients				
Ingredient Name			Strength	
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)				
GLYCERIN (UNII: PDC6A3C0OX)				
WATER (UNII: 059QF0KO0R)				
Product Characteristics				
Color	brown	Score	no score	
Shape	OVAL	Size	7mm	
Flavor		Imprint Code	P	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0045-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0045-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category	Application Number or Monograph Citation		Marketing Start Date	Marketing End Date
NDA	NDA021924		12/01/2018	

TIROSINT

levothyroxine sodium capsule

Product Information				
Product Type		HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0050
Route of Administration		ORAL		
Active Ingredient/Active Moiety				
Ingredient Name			Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)			LEVOTHYROXINE SODIUM ANHYDROUS	150 ug
Inactive Ingredients				
Ingredient Name				Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)				
GLYCERIN (UNII: PDC6A3C00X)				
WATER (UNII: 059QF0KO0R)				
Product Characteristics				
Color	brown	Score	no score	
Shape	OVAL	Size	7mm	
Flavor		Imprint Code	S	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0050-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0050-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA		NDA021924	12/01/2018	

TIROSINT				
levothyroxine sodium capsule				
Product Information				

Product Type		HUMAN PRESCRIPTION DRUG		Item Code (Source)		NDC:71858-0055		
Route of Administration		ORAL						
Active Ingredient/Active Moiety								
Ingredient Name				Basis of Strength		Strength		
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)				LEVOTHYROXINE SODIUM ANHYDROUS		175 ug		
Inactive Ingredients								
Ingredient Name						Strength		
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)								
GLYCERIN (UNII: PDC6A3C00X)								
WATER (UNII: 059QF0KO0R)								
Product Characteristics								
Color		brown		Score		no score		
Shape		OVAL		Size		7mm		
Flavor				Imprint Code		U		
Contains								
Packaging								
#	Item Code	Package Description			Marketing Start Date		Marketing End Date	
1	NDC:71858-0055-4	3 in 1 CARTON			12/01/2018			
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product						
2	NDC:71858-0055-1	1 in 1 CARTON			12/01/2018			
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product						
Marketing Information								
Marketing Category		Application Number or Monograph Citation			Marketing Start Date		Marketing End Date	
NDA		NDA021924			12/01/2018			

TIROSINT

levothyroxine sodium capsule

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0060

Route of Administration		ORAL		
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)		LEVOTHYROXINE SODIUM ANHYDROUS	200 ug	
Inactive Ingredients				
Ingredient Name			Strength	
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)				
GLYCERIN (UNII: PDC6A3C0OX)				
WATER (UNII: 059QF0KO0R)				
Product Characteristics				
Color	brown	Score	no score	
Shape	OVAL	Size	7mm	
Flavor		Imprint Code	Y	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0060-4	3 in 1 CARTON	12/01/2018	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0060-1	1 in 1 CARTON	12/01/2018	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA		NDA021924	12/01/2018	

TIROSINT			
levothyroxine sodium capsule			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71858-0017
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	62.5 ug

Inactive Ingredients	
Ingredient Name	Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
GLYCERIN (UNII: PDC6A3C0OX)	
WATER (UNII: 059QF0KO0R)	

Product Characteristics			
Color	brown	Score	no score
Shape	OVAL	Size	7mm
Flavor		Imprint Code	L
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71858-0017-4	3 in 1 CARTON	03/01/2023	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:71858-0017-1	1 in 1 CARTON	03/01/2023	
2		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021924	03/01/2023	

Labeler - IBSA Pharma Inc. (081215551)